Skip to the answer

Dabigatran Etexilate Uses, Dosage, Side Effects and Interactions

Brand name
Pradaxa

Pradaxa was the first dabigatran etexilate product the FDA approved, in October 2010. A generic is listed for its capsules, but not for its oral pellets.

Dabigatran etexilate is a blood thinner (direct thrombin inhibitor) used to lower stroke risk in non-valvular atrial fibrillation and to prevent or treat dangerous blood clots in the legs and lungs, in adults and in children.

Dr. Brian Staiger, PharmD, BCPS
Last reviewed Jul 10, 2026 Content updated Nov 7, 2026 Where our facts come from

Quick links

Ask Anything About Dabigatran EtexilateType a question in your own words. Answered from its FDA label in seconds.

Every other section of this page is in the dots on the left edge of your screen: point at one to see where it goes.Every other section of this page is one tap away: use the arrow tab on the left edge of your screen.

Dabigatran Etexilate in Short

The Pharmacist’s Take

Dr. Brian Staiger, PharmD, BCPS
Clinical pharmacist Written

Dabigatran etexilate (Pradaxa) is a blood thinner that blocks thrombin, a clotting protein, to lower stroke risk in atrial fibrillation not caused by a valve problem and to treat and prevent leg and lung clots; on the market since about 2010, with generics approved, it is a familiar warfarin alternative that skips routine clotting blood tests. Most people tolerate it well, though indigestion and upper stomach pain are common (food often helps) and bruising comes more easily. Bleeding is the main risk, and the boxed warning adds that stopping early can bring on a clot or stroke, so never stop it on your own.

Key Takeaways From the HelloPharmacist Team

  • Swallow the capsules whole, usually twice a day, and never open, chew or break them, since that raises how much drug you absorb.
  • Get help right away for bleeding that will not stop, black or bloody stools, vomiting blood, or sudden unusual weakness.
  • Check with your pharmacist before taking ibuprofen, naproxen or aspirin, which add to bleeding risk; acetaminophen is usually the safer pain choice.
  • Tell every doctor and dentist you take it before any procedure, and report leg numbness or weakness promptly after a spinal or epidural.

How we write and review this content: our editorial policy

FDA Boxed WarningThe FDA’s strongest safety alert. Read what it says about Dabigatran Etexilate.

Stopping dabigatran too early can raise your risk of a dangerous blood clot or stroke. Do not stop unless your doctor tells you to. If it must be stopped for a reason other than bleeding or finishing treatment, your doctor may cover you with another blood thinner.

Spinal or epidural bleeding: if you have an epidural, spinal anesthesia or spinal puncture while on this medicine, a blood clot can press on the spinal cord and cause long-term or permanent paralysis. Risk is higher with an indwelling epidural catheter, NSAIDs, platelet inhibitors or other blood thinners, past repeated spinal punctures, or spinal deformity or surgery. Report back pain, numbness, tingling, leg weakness, or bowel or bladder problems right away.

Read the full warning on DailyMed →

Dabigatran Etexilate by the Numbers

Strengths
9
across 2 forms
Makers and packagers
17
Earliest FDA record
2010
Rank by Medicaid prescriptions
#704 of 1,682 drugs
More prescriptions than 58% of the 1,682 drugs we measure
36,481 prescriptions, Q1–Q4 2025

Patient Information Guide for Dabigatran Etexilate

What It’s Used For

Dabigatran etexilate is a blood thinner used to prevent and treat clots.

  • Capsules, adults: lower stroke and systemic embolism risk in non-valvular atrial fibrillation.
  • Capsules, adults: treat DVT and PE after 5-10 days of an injected or IV blood thinner.
  • Capsules, adults: lower the risk of DVT and PE coming back.
  • Capsules, adults: prevent DVT and PE after hip replacement surgery.
  • Pradaxa capsules and some other dabigatran capsules, ages 8 to under 18: treat VTE and lower the risk of recurrence.
  • Pradaxa oral pellets, ages 3 months to under 12: treat VTE and lower the risk of recurrence.

How It Works

Dabigatran is a direct thrombin inhibitor. Thrombin turns fibrinogen into fibrin, which builds clots. By blocking thrombin, including thrombin stuck in a clot, dabigatran helps prevent clots from forming. It also reduces thrombin-driven platelet clumping.

Drug Class

Drug Class

  • Direct Thrombin Inhibitor

From Dabigatran Etexilate’s FDA label.

Detailed classifications and sources

The FDA sorts a drug’s active ingredient by how it works, what it does in the body and its chemical structure, and gives it one main drug class.

Drug Class

Established Pharmacologic Class (EPC)
  • Direct Thrombin Inhibitor

The main drug class the FDA gives it. It is the class named on the drug’s label.

What It Does in the Body

Physiologic effect (PE)

None listed for Dabigatran Etexilate in the FDA’s index.

From our Patient Information GuideDabigatran is a direct thrombin inhibitor. Thrombin turns fibrinogen into fibrin, which builds clots. By blocking thrombin, including thrombin stuck in a clot, dabigatran helps prevent clots from forming. Read How Dabigatran Etexilate Works

A change it makes in how the body works.

Drug Family

WHO ATC classification
  • Direct thrombin inhibitors

How the World Health Organization groups it: by the part of the body it acts on and what it treats.

The drug class comes from Dabigatran Etexilate’s FDA label. The description under What It Does in the Body is written by the HelloPharmacist team, not the FDA. Read the FDA’s definitions. The drug family is the World Health Organization’s ATC classification, from the U.S. National Library of Medicine’s RxClass. Reference only, not medical advice.

Dosage

Capsules are taken by mouth, with or without food, and swallowed whole. Most uses are twice daily; hip replacement prevention is once daily.

Pradaxa oral pellets are twice daily for children who can swallow soft food.

  • Do not swap forms milligram for milligram.
  • Do not combine forms to make up a dose.
  • Your doctor may pause it before surgery and restart it promptly.

Follow your prescriber and label.

Typical Doses

Your prescriber chooses your dose, so take it exactly as prescribed.

Dabigatran Etexilate Capsules

Lowering stroke risk in atrial fibrillation not caused by a heart valve problem
Adults Usual dose 75 mg twice a day
  • Reduce dosage to 75 mg twice daily

Good to know

CrCl < 30 mL/min with P-gp inhibitors: avoid co-administration

CrCl means creatinine clearance, a measure of how well the kidneys work.

Adults with kidney function (CrCl) above 30 mL/min Usual dose 150 mg twice a day

CrCl means creatinine clearance, a measure of how well the kidneys work.

Adults with severe kidney problems (CrCl 15 to 30 mL/min) Usual dose 75 mg twice a day

CrCl means creatinine clearance, a measure of how well the kidneys work.

Treating blood clots in the leg or lung (DVT and PE)
For adults with kidney function (CrCl) above 30 mL/min
Usual dose 150 mg twice a day
  • 150 mg orally, twice daily after 5-10 days of parenteral anticoagulation

Good to know

CrCl < 50 mL/min with P-gp inhibitors: avoid co-administration

DVT stands for deep venous thrombosis.

PE stands for pulmonary embolism.

CrCl means creatinine clearance, a measure of how well the kidneys work.

Lowering the chance of blood clots in the leg or lung coming back (DVT and PE)
For adults with kidney function (CrCl) above 30 mL/min
Usual dose 150 mg twice a day
  • 150 mg orally, twice daily after previous treatment

Good to know

CrCl < 50 mL/min with P-gp inhibitors: avoid co-administration

DVT stands for deep venous thrombosis.

PE stands for pulmonary embolism.

CrCl means creatinine clearance, a measure of how well the kidneys work.

Preventing blood clots in the leg or lung after hip replacement surgery
For adults with kidney function (CrCl) above 30 mL/min
Starting dose 110 mg once on the first day Usual dose 220 mg once a day

Step by step

  1. 110 mg for first day, then 220 mg once daily
  2. First dose 1-4 hours after surgery and after hemostasis, then 220 mg once daily for 28-35 days

Good to know

CrCl <50 mL/min with P-gp inhibitors: avoid co-administration

CrCl means creatinine clearance, a measure of how well the kidneys work.

See the Full Dosing Instructions on DailyMed →

Pradaxa

Treating or preventing return of blood clots (VTE) in children
Babies 3 to less than 6 months old, 3 kg to less than 4 kg Usual dose 30 mg twice a day
  • 30 mg twice daily (one 30 mg packet twice daily)
Babies 3 to less than 10 months old, 4 kg to less than 5 kg Usual dose 40 mg twice a day
  • 40 mg twice daily (one 40 mg packet twice daily)
Children 2 to less than 12 years old, 11 kg to less than 13 kg Usual dose 110 mg twice a day
  • 110 mg twice daily (one 110 mg packet twice daily)

See the Full Dosing Instructions on DailyMed →

Side Effects

The most common effects are stomach problems and bleeding.

Common side effects

  • Bleeding (including bruising or nosebleeds)
  • Indigestion or upper stomach pain
  • Nausea
  • Diarrhea
  • Stomach irritation or gastritis-like symptoms (such as reflux)

When to get medical help

  • Signs of serious bleeding, such as a big drop in blood pressure, unusual weakness or blood loss. Get help right away.
  • Back pain, numbness, tingling or weakness in the legs, or bowel or bladder problems, especially after a spinal or epidural procedure. Report immediately.
  • Signs of a severe allergic reaction, such as hives, swelling or trouble breathing.
  • Bleeding in the stomach or gut, or bleeding that will not stop.
  • Any new stroke or clot symptoms if you have stopped the medicine.

Warnings and Precautions

  • Bleeding: serious and sometimes fatal. Higher with kidney impairment, older age, and drugs that affect clotting.
  • Stopping early: raises clot and stroke risk.
  • Spinal or epidural hematoma: can cause permanent paralysis after spinal procedures.
  • Mechanical heart valves: must not use it.
  • Bioprosthetic valves and triple-positive antiphospholipid syndrome: not recommended.

Interactions

Some drugs change how much dabigatran is in your body or add to bleeding risk.

  • Rifampin (a P-gp inducer): lowers dabigatran levels, so generally avoid.
  • Dronedarone and systemic ketoconazole (P-gp inhibitors): raise levels and may need a dose change or avoidance.
  • Antiplatelet drugs, heparin, clot-dissolving drugs and long-term NSAIDs: add to bleeding risk.

Interactions Listed in the FDA-Approved Label

From the Dabigatran Etexilate prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.

  • P-gp inducers For example: rifampin
    What happensReduces exposure to dabigatran.
    What to doShould generally be avoided.
  • P-gp inhibitors dronedarone or systemic ketoconazole (adults with CrCl 30-50 mL/min, atrial fibrillation)
    What happensExpected to produce dabigatran exposure similar to that seen in severe renal impairment.
    What to doReduce the dosage to 75 mg twice daily.
  • P-gp inhibitors in patients with CrCl < 50 mL/min (DVT/PE treatment, recurrence, or hip surgery prophylaxis) or CrCl 15-30 mL/min (atrial fibrillation)
    What happensIncreased dabigatran exposure compared with either factor alone.
    What to doAvoid concomitant use.
  • Verapamil, amiodarone, quinidine, clarithromycin, ticagrelor
    What happensUse of these P-gp inhibitors does not require a dosage adjustment of dabigatran etexilate capsules.
    What to doResults should not be extrapolated to other P-gp inhibitors.
  • Proton pump inhibitors, H2 antagonists, digoxin
    What happensDid not appreciably change the trough concentration of dabigatran.
Read the label’s full interactions text

7 DRUG INTERACTIONS • P-gp inducers: Avoid coadministration with dabigatran etexilate capsules • P-gp inhibitors in adult patients with CrCl 30-50 mL/min: Reduce dosage or avoid • P-gp inhibitors in adult patients with CrCl < 30 mL/min: Not recommended 7.1 Reduction of Risk of Stroke and Systemic Embolism in Non-valvular Atrial Fibrillation in Adult Patients The concomitant use of dabigatran etexilate capsules with P-gp inducers (e.g., rifampin) reduces exposure to dabigatran and should generally be avoided. P-gp inhibition and impaired renal function are the major independent factors that result in increased exposure to dabigatran. Concomitant use of P-gp inhibitors in patients with renal impairment is expected to produce increased exposure of dabigatran compared to that seen with either factor alone. In patients with moderate renal impairment (CrCl 30-50 mL/min), reduce the dosage of dabigatran etexilate capsules to 75 mg twice daily when administered concomitantly with the P-gp inhibitors dronedarone or systemic ketoconazole. The use of the P-gp inhibitors verapamil, amiodarone, quinidine, clarithromycin, and ticagrelor does not require a dosage adjustment of dabigatran etexilate capsules. These results should not be extrapolated to other P-gp inhibitors. The concomitant use of dabigatran etexilate capsules and P-gp inhibitors in patients with severe renal impairment (CrCl 15-30 mL/min) should be avoided.

Excerpted: the section continues on the label. Read the full Drug Interactions section on DailyMed →

Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.

Before You Start

  • Do not use with active bleeding, a mechanical heart valve, or a past serious allergy to dabigatran.
  • Tell your doctor about kidney disease, since it raises drug levels.
  • Older adults have higher bleeding risk.
  • Pregnancy: data are limited; discuss with your doctor.
  • Breastfeeding is not recommended.
  • Children not studied with eGFR below 50 should avoid it.

Overdose

Too much can cause bleeding. The treatment is to stop the drug, investigate the bleeding source and give supportive care. In adults, a reversal agent (idarucizumab) is available, and hemodialysis can remove some dabigatran.

Half-Life and How Your Body Processes It

The drug is absorbed as dabigatran etexilate and converted to active dabigatran. Only about 3% to 7% is absorbed. Food delays peak levels by about 2 hours but does not change the amount absorbed. It is cleared mainly through the kidneys, with a half-life of about 12 to 17 hours in healthy adults. Kidney impairment raises exposure and lengthens the half-life.

Storage

Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) . Store in the original package to protect from moisture.

Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI

Dabigatran Etexilate: Pharmacist Answers to Common Questions

Quick, plain-English answers to the questions patients ask most about Dabigatran Etexilate — the kind of thing our pharmacy team would talk through with you at the counter.

Can I stop taking dabigatran suddenly?

No, please talk to your doctor first. Stopping early raises your risk of a dangerous clot or stroke. If you must stop, your doctor may cover you with another blood thinner.

Should I take dabigatran with food?

Capsules can be taken with or without food. Food slows absorption a little but does not change how much you absorb. Swallow them whole, and never open, chew or break them.

What side effects should I expect?

Stomach upset like indigestion, upper stomach pain, nausea or diarrhea is common, and bruising or bleeding can happen. Call your doctor for bleeding that won't stop, black or bloody stools, or unusual weakness.

What medicines should I avoid with dabigatran?

Tell us about everything you take. Rifampin should generally be avoided. Dronedarone and ketoconazole can raise dabigatran levels. NSAIDs, antiplatelets and other blood thinners raise your bleeding risk.

Is dabigatran safe if I'm pregnant or breastfeeding?

Pregnancy data are limited, and blood thinners can raise bleeding risk for mother and baby, so talk to your doctor if you plan to become pregnant. Breastfeeding is not recommended during treatment.

What should I tell my doctor before surgery or a spinal procedure?

Tell them you take dabigatran. It is often paused before procedures and then restarted promptly. If you have spinal or epidural anesthesia, report back pain, numbness, leg weakness, or bowel or bladder changes right away.

Is dabigatran etexilate available over the counter?

No. Dabigatran etexilate is a prescription medicine: every dabigatran etexilate product listed with the FDA is prescription only, so it is not sold over the counter. Your prescriber decides whether it is appropriate for you, and your pharmacist dispenses it.

When was dabigatran etexilate first available?

The earliest FDA record we hold for dabigatran etexilate is from 2010: its first approval in Drugs@FDA or its earliest product listing in the NDC Directory, whichever is older. Many older medicines were in use before their first formal FDA approval, so this is the earliest date on record, not necessarily when dabigatran etexilate was first used.

Who makes dabigatran etexilate?

17 companies currently list dabigatran etexilate products in the FDA's NDC Directory, including Boehringer Ingelheim Pharmaceuticals, Inc., A-S Medication Solutions, Alembic Pharmaceuticals Inc.. That count includes repackagers and distributors as well as manufacturers (companies that sell only the raw ingredient are not counted), so fewer companies actually make it; the label on your bottle names the one that supplied yours.

What is the brand name of dabigatran etexilate?

Dabigatran etexilate is the generic name. Its brand name is Pradaxa. Generic versions are listed under the name dabigatran etexilate.

What is the generic name of Pradaxa?

The generic name of Pradaxa is dabigatran etexilate. A generic name is the name of the active ingredient, the same whichever company makes the medicine; a brand name belongs to one company. Your prescription label may show either name.

What drug class is dabigatran etexilate?

The FDA groups dabigatran etexilate as Direct Thrombin Inhibitor.

Is there a generic version of dabigatran etexilate?

Yes. FDA-approved generic versions of dabigatran etexilate are listed in the FDA's National Drug Code Directory. A listing does not prove that every pharmacy stocks one, so your pharmacy can tell you which version it carries.

What strengths does dabigatran etexilate come in?

Dabigatran etexilate is listed in the FDA's National Drug Code Directory in these forms and strengths. Capsule (by mouth): 75 mg, 110 mg and 150 mg. Oral pellets (by mouth): 20 mg, 30 mg, 40 mg, 50 mg, 110 mg and 150 mg. A listing does not mean every pharmacy stocks every strength.

How much does dabigatran etexilate cost?

What you pay depends on your insurance, your pharmacy and the strength you take. As a benchmark, pharmacies paid a national average of $0.72 to $0.87 per generic capsule across 3 strengths and $3.16 to $3.18 per capsule of brand-name Pradaxa across 3 strengths as of November 18, 2026 (CMS's NADAC survey). That is the pharmacy's own cost for the medicine, not the price at the counter. No national price was found for dabigatran etexilate oral pellets. The pharmacy prices section of this page lists every strength priced.

Is there a dabigatran etexilate shortage?

No. Dabigatran etexilate is not on the FDA's drug shortage list as of Nov 22, 2026. A single pharmacy can still run short for a while without a national shortage, and your pharmacist can tell you what they are seeing.

Where can I read the dabigatran etexilate prescribing information (package insert)?

The full FDA-approved prescribing information for dabigatran etexilate, also called the package insert or drug label, is published on DailyMed, the National Library of Medicine's library of FDA labels. Each company's version has its own label; this page is built from Boehringer Ingelheim Pharmaceuticals, Inc.'s, revised Jun 27, 2025, and links to it on DailyMed.

Can you crush dabigatran etexilate?

Some forms of dabigatran etexilate are on our Do Not Crush list of tablets and capsules that should not be crushed or chewed: Dabigatran etexilate mesylate (capsule); Pradaxa (capsule). They are listed for a reason such as irritation, a bad taste or a special formulation. A form that is not on the list may still come with its own instructions, so check the label and ask your pharmacist before you crush, split or open any medicine. Each listed form’s reason and instructions are on our Do Not Crush list.

Is dabigatran etexilate gluten free?

No dabigatran etexilate label we read lists an ingredient made from wheat, barley or rye, the grains that carry gluten, and none names a starch, dextrin or maltodextrin without saying where it comes from. We read the FDA labels of 49 dabigatran etexilate products from 17 companies. A label lists ingredients; it is not a gluten test, so we cannot promise that any product has no gluten. If you have celiac disease, ask the company for a written gluten statement. Our Inactive Ingredient Checker shows each company's dabigatran etexilate by strength and NDC, and whether its label lists a gluten source, lactose, dyes or any other inactive ingredient. See dabigatran etexilate inactive ingredients by company

Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI

Ask Anything About Dabigatran Etexilate

Skip the scrolling. Ask in your own words and get an answer from Dabigatran Etexilate’s FDA label and our pharmacists’ own work.

Try:

Name another drug or a supplement in your question and we check both.

AI answers from FDA labels and our own records, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.How this works
  • Sources: Dabigatran Etexilate’s FDA label, including the clinical studies it reports, and the label of any drug you name; our pharmacists’ own work, such as our Do Not Crush list and our published answers to readers’ questions; our pharmacy prices and the Natural Medicines supplement database.
  • Written by AI: Answers are written by AI from those sources, and AI can make mistakes. Check what you read here with your doctor or pharmacist before you act on it.
  • Reviewed afterward: Our pharmacy team reviews every question and answer afterward to check it for accuracy, and when we find an error, we correct how the box answers. Read more in How we use AI.
  • Not medical advice. In an emergency, call 911, Poison Control at 1-800-222-1222, or 988.

More About Dabigatran Etexilate on HelloPharmacist

Still have a question? A licensed pharmacist answers for free, as soon as they can.
Detailed Data & References for Dabigatran Etexilate Forms and strengths, pricing, billing codes, manufacturers, safety reports and sourcing: the data behind the page. Most people can stop here. Each section below opens on a tap.

Dabigatran Etexilate Forms and Strengths (How It Comes)

Dabigatran Etexilate comes in 2 dose forms. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.

Need a version that does not list lactose, a gluten source, a dye or gelatin? Inactive ingredients differ by manufacturer: see Dabigatran Etexilate inactive ingredients by manufacturer.

Capsule

By mouth
Brands Pradaxa (the first brand, 2010)
How this form is used
What it may be used for
  • Dabigatran etexilate capsules are used in adults for stroke prevention in non-valvular atrial fibrillation, DVT and PE treatment and recurrence prevention, and prevention after hip replacement.
  • Pradaxa capsules are also labeled for VTE treatment and recurrence prevention in children 8 to under 18.
Important instructions
  • Pradaxa capsules and dabigatran capsules can be taken with or without food.
  • Dabigatran capsules should not be broken, chewed or opened.
  • Pradaxa capsules are not substitutable milligram for milligram with other dabigatran forms.
Available strengths 3 strengths
45 FDA-listed product records ⓘ

Oral pellets

By mouth
Brands Pradaxa (the first brand, 2010)
How this form is used
What it may be used for
  • Pradaxa oral pellets treat VTE in children 3 months to under 12 after at least 5 days of an injected or IV blood thinner.
  • Pradaxa oral pellets lower the risk of VTE coming back in children 3 months to under 12.
Important instructions
  • Pradaxa oral pellets can be used once a child can swallow soft food.
  • Pradaxa oral pellets are given twice daily with a dose based on age and weight.
  • Pradaxa oral pellets are not swapped milligram for milligram with capsules, and forms should not be combined.
Available strengths 6 strengths
6 FDA-listed product records ⓘ

Dabigatran Etexilate on the U.S. Market: Products, Makers and Brands

How Dabigatran Etexilate appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.

17 companies list 51 Dabigatran Etexilate product records with the FDA, mostly as capsule, oral pellets; the earliest marketing or approval year on record is 2010. The one brand name in the directory today is Pradaxa; the rest are generics.

2
Dose forms ⓘ
17
Labelers (makers, repackagers, distributors)
1
Brand names ⓘ
51
FDA-listed product records ⓘ
2010
Earliest FDA record ⓘ

FDA-listed product records by dose form (tablet variants merged) — FDA National Drug Code Directory. Record counts are not sales or prescription volume.

Also listed with the FDA, not a patient dose form: Powder (24) · Pellet (1) — bulk drug substance and unfinished product sold to compounders and other manufacturers to finish, and multi-item kits. These aren’t counted in the dose-form total above.

Boehringer Ingelheim Pharmaceuticals, Inc.18%
A-S Medication Solutions10%
Alembic Pharmaceuticals Inc.6%
Alembic Pharmaceuticals Limited6%
Apotex Corp.6%
Ascend Laboratories, LLC6%
Other makers49%

Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.

How Widely Dabigatran Etexilate Is Used (Medicaid Data)

How many Dabigatran Etexilate prescriptions Medicaid paid for in Q1–Q4 2025, every brand, strength and form together. Medicaid is one program, so total U.S. use is higher.

36,481
Medicaid prescriptions filled (Q1–Q4 2025)
$7.2M paid by Medicaid, before rebates

How commonly is Dabigatran Etexilate prescribed? Of the 1,682 medications we measure, Dabigatran Etexilate ranks #704 by Medicaid prescriptions — more than 58% of them.

Where Dabigatran Etexilate ranks among the drugs we measure · Q1–Q4 2025 · neighbors ±5

Utilization by Dabigatran Etexilate product

Pick a strength and form to see its own numbers. Brand and generic versions are counted together.

The 150 mg oral capsule is the most-dispensed Dabigatran Etexilate product — about 97% of these Medicaid prescriptions.

dabigatran etexilate 150 MG Oral Capsule Most dispensed

35,434 Medicaid prescriptions (Q1–Q4 2025) 97% of Dabigatran Etexilate prescriptions shown $6.9M paid by Medicaid, before rebates ≈ $195 per prescription, before rebates

11 of 35 listed NDCs had Medicaid claims. RxNorm 1037045

dabigatran etexilate 75 MG Oral Capsule

665 Medicaid prescriptions (Q1–Q4 2025) 2% of Dabigatran Etexilate prescriptions shown $130,678 paid by Medicaid, before rebates ≈ $197 per prescription, before rebates

4 of 30 listed NDCs had Medicaid claims. RxNorm 1037179

dabigatran etexilate 110 MG Oral Capsule

382 Medicaid prescriptions (Q1–Q4 2025) 1% of Dabigatran Etexilate prescriptions shown $131,223 paid by Medicaid, before rebates ≈ $344 per prescription, before rebates

5 of 19 listed NDCs had Medicaid claims. RxNorm 1723476

Dollars are what Medicaid paid before the rebates drug makers send back, so its real cost is lower.

Source: Medicaid State Drug Utilization Data (CMS), all states. 20 of the 84 listed Dabigatran Etexilate NDCs had Medicaid claims.

Compare Dabigatran Etexilate Products

A representative set of FDA-listed product records for Dabigatran Etexilate — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)

Showing 51 of 51 products — FDA National Drug Code Directory. See every product, package size and price: browse all 51 Dabigatran Etexilate NDCs →

Dabigatran Etexilate Recall History

A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.

The FDA’s enforcement reports list 4 Dabigatran Etexilate recalls since July 2021, covering 9 product listings. All of them are still ongoing or began in the last six months. A recall names specific lots from one company, so check the lot number on your own bottle rather than assuming every product is affected; your pharmacist can check whether your supply came from an affected lot.

Ongoing Class III Jul 16, 2026 · Ascend Laboratories, LLC
Failed impurity/degradation specification: an OOS result observed in Related substance test analysis w.r.t Impurity II, Impurity III and Total impurities for 12-month stability
  • Dabigatran Etexilate Capsules, 75 mg, 30-count (3x10) blister pack further packaged in a carton, Rx only, Manufactured by: Alkem Laboratories Ltd., Mumbai, INDIA, Distributed by: MAJOR PHARMACEUTICAL… Lots: Lot: 25141586, Exp. April 30, 2027. FDA record D-0739-2026 →
  • Dabigatran Etexilate Capsules, 75 mg, 60-count (6x10)blister pack further packaged in a carton, Rx only, Manufactured by: Alkem Laboratories Ltd., Mumbai, INDIA, Distributed by: MAJOR PHARMACEUTICALS… Lots: Lot: 25141585, Exp. April 30, 2027. FDA record D-0738-2026 →
  • Dabigatran Etexilate Capsules, 150 mg, 60-count (6x10) blister pack further packaged in a carton, Rx only, Manufactured by: Alkem Laboratories Ltd., Mumbai, INDIA, Distributed by: MAJOR PHARMACEUTICA… Lots: Lot: 25141583, Exp. April 30, 2027. FDA record D-0737-2026 →
Ongoing Class III Jun 30, 2026 · Ascend Laboratories, LLC
Failed Impurities/Degradation Specifications: OOS result was observed during the related substance test analysis with respect to Impurity II, Impurity III and Total impurity testing for 12 Month Long-Term Stability.
  • Dabigatran etexilate Capsules, 150 mg, 20-count carton (2x10), Rx only, Manufactured by: Alkem Laboratories, Mumbai, INDIA, Distributed by: Major Pharmaceuticals, Indianapolis, IN 46268, NDC 0904-725… Lots: Lot: 25141584, Exp 4/30/2027. FDA record D-0736-2026 →
  • Dabigatran etexilate Capsules, 110 mg, 60-count carton (6x10), Rx Only, Manufactured by: Alkem Laboratories, Mumbai, INDIA, Distributed by: Major Pharmaceuticals, Indianapolis, IN 46268, NDC 0904-725… Lots: Lot: 25141707, Exp 4/30/2027. FDA record D-0735-2026 →
Ongoing Class II Dec 12, 2024 · Ascend Laboratories, LLC
CGMP Deviations: Presence of N-nitroso-Dabigatran impurity above recommended interim limit
  • Dabigatran Etexilate, 150mg capsules, 60-count bottles, Rx Only, Manufactured by: Alkem Laboratories Ltd., INDIA, Distributed by: Ascend Laboratories, LLC Parsippany, NJ 07054 NDC 67877-475-60 Lots: Lot #: 24142192, 24142193, 24142194, Exp. Date April 30, 2026; 24142463, Exp. Date May 31, 2026; FDA record D-0130-2025 →
  • Dabigatran Etexilate, 75 mg capsules, 60-count bottles, Rx Only, Manufactured by: Alkem Laboratories Ltd., INDIA, Distributed by: Ascend Laboratories, LLC Parsippany, NJ 07054 NDC 67877-474-60 Lots: Lot #: 24142328, 24142329, 24142330, Exp. Date May 31, 2026. FDA record D-0129-2025 →
Ongoing Class II Mar 14, 2023 · Ascend Laboratories, LLC
CGMP Deviations: Detection of N-nitroso-dabigatran (NDAB) impurity levels above the Acceptable Daily Intake Limit.
  • Dabigatran Etexilate 150mg Capsules, 150 mg, Rx Only, 60 Capsules per bottle, Manufactured by: Alkem Laboratories Ltd., INDIA, Distributed by: Ascend Laboratories, LLC Parsippany, NJ 07054, NDC 67877… Lots: Lot #s: 22142448, 22142449, 22142450, Exp 5/2024; 22143845, Exp 7/2024. FDA record D-0534-2023 →
  • Dabigatran Etexilate Capsules, 75 mg, Rx Only, 60 Capsules per bottle, Manufactured by: Alkem Laboratories Ltd., INDIA, Distributed by: Ascend Laboratories, LLC, Parsippany, NJ 07054, NDC 67877-474-6… Lots: Lot #s: 22142462, 22142463, 22142464, Exp 5/2024; 22143000, 22143001, 22143002, Exp 6/2024. FDA record D-0533-2023 →

Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Nov 19, 2026.

Dabigatran Etexilate in RxNorm: From Ingredient to Every Form and Strength

RxNorm is the U.S. National Library of Medicine’s standard name for every version of a medicine, the code pharmacy and prescribing systems share. This page starts from one ingredient (IN); each dose form (SCDF) branches from it, and each exact strength (SCD) from its form. Combination products are separate concepts with their own pages.

Dose forms
2
Strengths
9
Forms in current FDA listings
2 of 2
In current FDA listings No current FDA listing
Ingredient (IN) Dabigatran Etexilate RxCUI 1037042
  1. Dose form (SCDF) Oral Capsule RxCUI 1037044
    In current FDA listings
    Its 3 strengths (SCD)
  2. Dose form (SCDF) Oral Pellet RxCUI 2590615
    In current FDA listings
    Its 6 strengths (SCD)

RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.

What Dabigatran Etexilate Costs Pharmacies (NADAC Benchmark)

What pharmacies pay to buy Dabigatran Etexilate: the national average from CMS’s weekly NADAC survey, as of Nov 18, 2026. It is the pharmacy’s cost, not your price at the counter.

No national price was found for Dabigatran Etexilate oral pellets, so the prices below are for the capsules only.

How the Pharmacy Price Has Changed

Pick the generic or the brand and a strength to see how its price has changed since Nov 2023.

Version
Strength

At this strength, Pradaxa costs pharmacies $3.18 per capsule.

For the generic 75 mg capsule, pharmacies paid an average of $0.717 per capsule as of Nov 18, 2026, down 35% from $1.11 a year earlier. At this strength, Pradaxa costs pharmacies $3.18 per capsule.

What pharmacies pay now
$0.717
per capsule, as of Nov 18, 2026
Last 4 weeks
Up 0.3%
from $0.715 on Oct 21, 2026
Last 12 months
Down 35%
from $1.11 on Nov 19, 2025
Lowest and highest since Aug 2024
$0.715 to $2.19
per capsule

Each step is one weekly survey. Arrow keys on the chart move week by week.
See the numbers, month by month
Generic 75 mg capsule: the average pharmacy price per capsule, the last survey of each month
MonthPharmacy price
Nov 2026$0.717
Oct 2026$0.715
Sep 2026$0.750
Aug 2026$0.843
Jul 2026$0.899
Jun 2026$0.898
May 2026$0.870
Apr 2026$0.848
Mar 2026$0.942
Feb 2026$1.01
Jan 2026$1.05
Dec 2025$1.09
Nov 2025$1.11
Oct 2025$1.13
Sep 2025$1.10
Aug 2025$1.17
Jul 2025$1.31
Jun 2025$1.47
May 2025$1.52
Apr 2025$1.69
Mar 2025$1.77
Feb 2025$1.86
Jan 2025$1.94
Dec 2024$2.03
Nov 2024$2.19
Oct 2024$2.17
Sep 2024$2.09
Aug 2024$2.08
FormStrengthVersion What pharmacies pay
Capsule · Oral 75 mg Generic $0.717 per capsule NDC details & price history
Capsule · Oral 75 mg Pradaxa (brand) $3.18 per capsule NDC details & price history
Capsule · Oral 110 mg Generic $0.869 per capsule NDC details & price history
Capsule · Oral 110 mg Pradaxa (brand) $3.17 per capsule NDC details & price history
Capsule · Oral 150 mg Generic $0.773 per capsule NDC details & price history
Capsule · Oral 150 mg Pradaxa (brand) $3.16 per capsule NDC details & price history
Why it helps: it shows whether the drug itself is cheap or costly, and whether a cash price you are quoted is in a reasonable range. What you pay also depends on your insurance and pharmacy.

Source: CMS National Average Drug Acquisition Cost (NADAC). Each row spans the package sizes CMS priced; the generic and the brand are priced separately.

Dabigatran Etexilate Brand Names

Dabigatran Etexilate has one brand name on record: Pradaxa. A brand name is one company's name for the medicine; a generic has the same active ingredient under its generic name.

Pradaxa the first brand, 2010

Who Makes Dabigatran Etexilate: Manufacturers and Labelers

17 companies list Dabigatran Etexilate products with the FDA. By number of product records, the largest are Boehringer Ingelheim Pharmaceuticals, Inc., A-S Medication Solutions, Alembic Pharmaceuticals Inc.. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.

Boehringer Ingelheim Pharmaceuticals, Inc. 9 A-S Medication Solutions 5 Alembic Pharmaceuticals Inc. 3 Alembic Pharmaceuticals Limited 3 Apotex Corp. 3 Ascend Laboratories, LLC 3 Aurobindo Pharma Limited 3 Camber Pharmaceuticals, Inc. 3 Dr.Reddys Laboratories Inc 3 Major Pharmaceuticals 3 Novadoz Pharmaceuticals LLC 3 American Health Packaging 2 AvKARE 2 Mylan Pharmaceuticals Inc. 2 XLCare Pharmaceuticals, Inc. 2 AvPAK 1 NorthStar RxLLC 1

Sources for This Dabigatran Etexilate Page

Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.

📄
FDA-filed drug labels (SPL) Uses, dosing, warnings & side effects from SPL records retrieved through openFDA; the linked representative set can be verified on DailyMed. Prescribing information dated Jun 27, 2025, the label version this page reads. A label changes when the FDA approves new uses, doses or warnings, so this is not the day the page itself last changed. Read the full label on DailyMed
🏭
Forms, brands & labelersAggregated from ingredient-matched FDA National Drug Code Directory product records for Dabigatran Etexilate.
📈
Real-world reportsThe FDA Adverse Event Reporting System (FAERS), served through openFDA.
🚨
Recalls & shortagesopenFDA drug-enforcement reports and the FDA drug-shortage database.

Where this information comes from

The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 22 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source.

Clinical labels in scope
22
Finished products in the current FDA directory
51
Companies listing them (makers, repackagers, distributors)
17
FDA labeler codes behind them ⓘ
17
Linked representative label ⓘ
Boehringer Ingelheim Pharmaceuticals, Inc.
Linked label effective
Jun 27, 2025
Composite sections available
26
Linked SPL Set ID
9ac0a64a-8666-45f7-9d4f-40fd894f7e6d
Linked SPL Document ID
56b1a7c2-0afd-40c6-bda5-563e234a9f28
Open the linked representative label on DailyMed ↗

How this page is built

HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Boehringer Ingelheim Pharmaceuticals, Inc. is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →